Literature DB >> 7874667

The cost of schizophrenia.

D A Wasylenki1.   

Abstract

In 1988, the management of mental illness in the United States cost an estimated $129.3 billion which comprises direct costs (hospital/institution costs, health care provider fees, prescription drugs), indirect costs (reduced/lost productivity due to morbidity or mortality) and other costs including productivity of family caregivers. The largest mental health care expenditure is for schizophrenia due to the high prevalence of this illness, early age of onset, and pattern of chronicity. This paper reviews three aspects of the care of schizophrenia that have an impact on cost: 1. prevention of relapse; 2. provision of community care; and 3. use of new antipsychotic medications. Better compliance, community-based care incorporating clinical case management and improved treatments can be expected to lower costs while improving the quality of life and social functioning of patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7874667

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  10 in total

1.  Use of healthcare services by patients treated with risperidone versus conventional antipsychotic agents.

Authors:  Frank Gianfrancesco; Michael B Durkin; Ramy Mahmoud; Ruey-Hua Wang
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  [Psychiatry in transitions of the public health system].

Authors:  H Helmchen
Journal:  Nervenarzt       Date:  2004-11       Impact factor: 1.214

Review 3.  The Canadian experience with risperidone for the treatment of schizophrenia: an overview.

Authors:  M Iskedjian; M Hux; G J Remington
Journal:  J Psychiatry Neurosci       Date:  1998-09       Impact factor: 6.186

Review 4.  Olanzapine. A pharmacoeconomic review of its use in schizophrenia.

Authors:  R H Foster; K L Goa
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

Review 5.  Risperidone. A pharmacoeconomic review of its use in schizophrenia.

Authors:  R H Foster; K L Goa
Journal:  Pharmacoeconomics       Date:  1998-07       Impact factor: 4.981

Review 6.  New wine in old bottle: late-life psychosis.

Authors:  Alana Iglewicz; Thomas W Meeks; Dilip V Jeste
Journal:  Psychiatr Clin North Am       Date:  2011-06

7.  A community-based perspective.

Authors:  R Parthasarathy
Journal:  Indian J Psychiatry       Date:  2005-10       Impact factor: 1.759

8.  Overview and emerging trends.

Authors:  Sandeep Grover; Ajit Avasthi; Subho Chakrabarti; Paramanand Kulhara
Journal:  Indian J Psychiatry       Date:  2005-10       Impact factor: 1.759

9.  Comparative effectiveness of antipsychotic drugs in schizophrenia.

Authors:  T S Stroup; J A Lieberman; M S Swartz; J P McEvoy
Journal:  Dialogues Clin Neurosci       Date:  2000-12       Impact factor: 5.986

10.  Effects of medication adherence on hospitalizations and healthcare costs in patients with schizophrenia in Thailand.

Authors:  Piyameth Dilokthornsakul; Thitaporn Thoopputra; Oraluck Patanaprateep; Ronnachai Kongsakon; Nathorn Chaiyakunapruk
Journal:  SAGE Open Med       Date:  2016-03-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.